Clene polishes tarnished ALS asset with long-term survival data

Clene has shared another cut of long-term data from its phase 2 amyotrophic lateral sclerosis (ALS) trial. The open-label extension linked a gold nanocrystal suspension to improved survival, but, with setbacks including a primary endpoint miss hanging over it, Clene’s share price remains in the basement.